Skip to main content

Weber David M's Form 4 filing

Abiomed Inc (ABMD) · filed Feb 9, 2022

Accession no.
0001179110-22-000966
Filed
Feb 9, 2022
Trade date
Feb 7-9, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 8 non-derivative transactions and 1 derivative transaction. Open-market sales total $3.30M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Weber David MCIK 0001399519Officer (Chief Operating Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 7, 2022Common Stock, $.01 par valueMOption exerciseAcquired+300$21.55+$6,465131,614Direct
Feb 7, 2022Common Stock, $.01 par valueSSaleDisposed−300$300.25F6−$90,075131,314Direct
Feb 8, 2022Common Stock, $.01 par valueMOption exerciseAcquired+7,413$21.55+$159,750.15138,727Direct
Feb 8, 2022Common Stock, $.01 par valueSSaleDisposed−4,884$300.40F7−$1,467,153.6133,843Direct
Feb 8, 2022Common Stock, $.01 par valueSSaleDisposed−641$301.10F8−$193,005.1133,202Direct
Feb 8, 2022Common Stock, $.01 par valueSSaleDisposed−1,888$310.00F9−$585,280131,314Direct
Feb 9, 2022Common Stock, $.01 par valueMOption exerciseAcquired+3,112$21.55+$67,063.6134,426Direct
Feb 9, 2022Common Stock, $.01 par valueSSaleDisposed−3,112$310.19F10−$965,311.28131,314Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 7, 2022Common StockDReturned to the companyDisposed0$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F6

This price represents the sale price of the transactions on the reported date at $300.2533. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

Referenced by the price of 1 transaction in Table I.

F7

This price represents the sale price of the transactions on the reported date at $300.3973. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

Referenced by the price of 1 transaction in Table I.

F8

This price represents the sale price of the transactions on the reported date at $301.0966. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

Referenced by the price of 1 transaction in Table I.

F9

This price represents the sale price of the transactions on the reported date at $310.00. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

Referenced by the price of 1 transaction in Table I.

F10

This price represents the sale price of the transactions on the reported date at $310.19. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)